- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00866281
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
November 18, 2015 updated by: Novartis Pharmaceuticals
A Phase I/II, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients With Relapsed or Refractory Leukemia
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory acute leukemias that may benefit from administration of midostaurin, including MLL-rearranged ALL and FLT3 positive AML.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris Cedex 19, France, 75935
- Novartis Investigative Site
-
-
-
-
GE
-
Genova, GE, Italy, 16147
- Novartis Investigative Site
-
-
MB
-
Monza, MB, Italy, 20900
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00165
- Novartis Investigative Site
-
-
TO
-
Torino, TO, Italy, 10126
- Novartis Investigative Site
-
-
-
-
-
Rotterdam, Netherlands, 3015 GJ
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Sweden, SE-171 76
- Novartis Investigative Site
-
-
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital CPKC412A2114
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mixed-lineage leukemia (MLL) gene rearranged Acute Lymphoblastic Leukemia (ALL), that does not respond to treatment or has relapsed from prior treatment; or FLT3 mutated Acute Myeloid Leukemia (AML) that does not respond to a second treatment or has relapsed from 2 prior treatments
- Normal organ function, and chest x-ray
- Expected survival greater than 8 weeks
- Can care for most of personal needs and perform at least minimum activity
Exclusion Criteria:
- Patients with symptomatic leukemic central nervous system involvement or isolated extramedullary leukemia
- Patients must not have received other treatments for leukemia within a predefined time period, 72 hours for medications, 2 months for transplants
- Patients with heart function that is not normal
- Patients with HIV or hepatitis
- Patients with another severe disease or medical condition besides leukemia Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 30 mg/m^2 bid
Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m^2 twice daily (bid) through oral route.
The total daily dose in 30 mg/m^2 bid cohort was 60 mg/m^2.
|
Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water.
The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
Other Names:
|
Experimental: 60 mg/m^2 bid
Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m^2 bid through oral route.
The total daily dose in 60 mg/m^2 bid cohort was 120 mg/m^2.
|
Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water.
The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Midostaurin- Posterior Probability of DLT
Time Frame: Baseline, End of dose escalation phase (6 months)
|
MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced dose limiting toxicity (DLT), based on a Bayesian logistic regression model (BLRM) employing the escalation with overdose control (EWOC) principle.
A DLT was defined as a grade 3 or 4 non-hematological adverse event (AE) or abnormal laboratory value related to study drug.
Mean and the 95% posterior probability estimates of having a DLT by age strata and dose is presented.
Estimation of MTD and/or recommended dose for expansion (RDE) at the dose-escalation phase of the study was based upon the estimation of the probability of DLT for participants in the dose-determining set (DDS).
|
Baseline, End of dose escalation phase (6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Best Overall Response by Indication
Time Frame: Baseline, Day 15 (Day 1 of Cycle 2), Day 22 (Day 8 of Cycle 2), Day 29(Day 1 of Cycle 9), End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
The best overall clinical response was determined as per the clinical assessment done by the investigator.
Responders were defined as all participants with a best clinical response of leukemia free state, morphological complete remission, incomplete morphological complete remission, partial remission, bone marrow blast response, bone marrow minor blast response, peripheral blood blast response, minor peripheral blood blast response.
Participants with stable disease, progressive disease and with missing tumour assessment or who discontinued the study or who died before having their first assessment were considered as non-responders.
Stable disease was defined as failure to achieve any of the above response.
Progressive disease was defined as doubling of the bone marrow blast percentage from baseline in participants with <40% bone marrow blasts at baseline, or a 50% increase in bone marrow blast percentage from baseline in participants with >40% bone marrow blasts at baseline,
|
Baseline, Day 15 (Day 1 of Cycle 2), Day 22 (Day 8 of Cycle 2), Day 29(Day 1 of Cycle 9), End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
Time to Response With Midostaurin
Time Frame: Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
Time to response was defined as the time from the date of start of midostaurin treatment to the date of first response.
The best overall clinical response was determined as per the clinical assessment done by the investigator.
Responders were defined as all participants with a best clinical response of leukemia free state, morphological complete remission, incomplete morphological complete remission, partial remission, bone marrow blast response, bone marrow minor blast response, peripheral blood blast response, minor peripheral blood blast response.
Time to response was calculated by using the formula = (date of first response -date of start of midostaurin) +1 day.
|
Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
Overall Survival With Midostaurin
Time Frame: Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
Overall survival (OS) was defined as the time from start of treatment to date of death due to any cause.
The percentage (%) event-free probability estimates were obtained from the Kaplan-Meier survival estimates.
|
Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
Plasma Concentrations of Midostaurin and Its Metabolites CGP52421 and CGP62221
Time Frame: Day 1, Day 5, Day 7, Day 15 (Day 1 of Cycle 2), Day 29 (Day 1 of Cycle 3)
|
The plasma concentrations of midostaurin (PKC412) and its two major metabolites, CGP62221 and CGP52421 were determined by using a validated liquid chromatography/tandem mass spectrometry method.
|
Day 1, Day 5, Day 7, Day 15 (Day 1 of Cycle 2), Day 29 (Day 1 of Cycle 3)
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs or SAEs and Death During the Study
Time Frame: Baseline (start of study treatment) up to End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug.
A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.
Treatment related AEs or SAEs were defined as AEs or SAEs that were suspected to be related to study treatment as per investigator.
On treatment death was a fatal event leading to permanent cessations of all vital functions of the body.
|
Baseline (start of study treatment) up to End of treatment (up to 24 months after last dose or until death whichever occurred first)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
September 1, 2014
Study Completion (Actual)
September 1, 2014
Study Registration Dates
First Submitted
March 19, 2009
First Submitted That Met QC Criteria
March 19, 2009
First Posted (Estimate)
March 20, 2009
Study Record Updates
Last Update Posted (Estimate)
December 22, 2015
Last Update Submitted That Met QC Criteria
November 18, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Midostaurin
Other Study ID Numbers
- CPKC412A2114
- 2008-006931-11 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on midostaurin
-
University Medical Center GroningenUnknown
-
Novartis PharmaceuticalsAvailableAcute Myeloid Leukemia | Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic Neoplasm | FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
-
Novartis PharmaceuticalsCompletedAML and High Risk MDSGermany, Italy, France, Netherlands, United States, Australia, Japan
-
Novartis PharmaceuticalsCompletedLeukemiaUnited States, Belgium, Netherlands, Canada, Austria, Germany, Australia, United Kingdom, Turkey, France, Poland, Norway
-
Technische Universität DresdenNovartis PharmaceuticalsCompletedAcute Myeloid LeukemiaGermany
-
University of KansasNovartisCompletedAcute Myeloid LeukemiaUnited States
-
Technische Universität DresdenPfizer; Novartis PharmaceuticalsRecruiting
-
Novartis PharmaceuticalsRecruitingFollicular Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B-cell LymphomaBrazil
-
Richard Stone, MDMassachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's HospitalActive, not recruitingRAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDSAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
Novartis PharmaceuticalsNo longer availableFLT3-mutated Acute Myeloid LeukemiaCanada